Get started
Author

Mallika Sachdev Dhawan

Observed names: M. Dhawan, Mallika Dhawan, Mallika S. Dhawan
Institution: Genentech
ORCID: 0000-0001-8338-4238
Observed ORCID: 0000-0001-8338-4238
OpenAlex ID: A5000765851
Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors
2017 · Mallika S. Dhawan, Imke H. Bartelink, et al. · Clinical Cancer Research · 78
Phase 1 study of ANDES-1537: A novel antisense oligonucleotide against non-coding mitochondrial DNA in advanced solid tumors.
2018 · Mallika Sachdev Dhawan, Rahul Raj Aggarwal, et al. · Journal of Clinical Oncology · 25
512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies
2021 · R. Aggarwal, S. Umetsu, et al. · Annals of Oncology · 17
PDF
Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors.
2020 · Benedito A. Carneiro, Ludimila Cavalcante, et al. · Journal of Clinical Oncology · 14
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al. · Clinical Cancer Research · 13
PDF
A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies
2022 · Erica S. Tsang, Rahul R. Aggarwal, et al. · Cancer Research Communications · 6
Glycogen synthase kinase-3 beta (GSK-3β) blockade with 9-ing-41 in gastrointestinal cancers: The 1801 phase Ib/II study.
2020 · Howard Safran, Mallika Sachdev Dhawan, et al. · Journal of Clinical Oncology · 2
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al. · Clinical Cancer Research · 1
Updated survival follow-up for phase I study of abexinostat with pazopanib in patients with solid tumor malignancies.
2022 · Erica S Tsang, Rahul Raj Aggarwal, et al. · Journal of Clinical Oncology · 1
Supplementary Table S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Figure S1 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Data from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Figure S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Figure S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Supplementary Table S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Supplementary Data Table S4 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Figure S2 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Supplementary Data Table S3 from Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
2026 · Emmanuel S. Antonarakis, Qing Cao, et al.
Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer Patients
2026 · Julia Suchomel, Christine M. Bowman, et al. · Clinical and Translational Science
Supplementary Table S2 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S5 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Figure S2 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Methods S1 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S1 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Supplementary Table S12 from Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
2024 · Petros Grivas, Elena Garralda, et al.
Works count: 46
Citation count: 157
H-index: 6
I10-index: 5
Year
Topic
Type